Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs Novo Nordisk A/S — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.25, while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BND | NVO | |
|---|---|---|
52-Week High | $75.17 | $63.98 |
52-Week Low | $72.15 | $35.29 |
Market Cap | — | $207.85B |
Sector | — | Health |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.28, up 0.18% on the day, with a bearish technical signal driven by moving averages. Recent corporate actions include dividend payments of $0.25-$0.24, with the next scheduled for August 5, 2026. The ETF's neutral oscillators and flat support/resistance at $72 suggest consolidation. News highlights focus on bond ETF inflows and institutional positioning shifts.
The outlook remains cautious amid rising Treasury yields and inflation concerns. Opportunities lie in BND's role as a core fixed-income holding for diversification, but risks include interest rate sensitivity and macroeconomic volatility. Investor sentiment is mixed, balancing yield appeal against bond market headwinds.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
